Barbara Sarina2021-05-12T10:50:42+02:00Ruxolitinib nel trattamento della cGVHD refrattaria a steroide: revisione della letteratura e risultati dello studio randomizzato REACH 3 (Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 StudyBarbara Sarina2021-05-12T10:50:42+02:0026 Marzo 2021|
Iacopo Peccatori2021-03-04T10:38:15+01:00HHV6 e trapiantoIacopo Peccatori2021-03-04T10:38:15+01:005 Febbraio 2021|
Commento a cura di: Dottor Davide Leardini e Dottor Riccardo Masetti2021-05-12T10:52:17+02:00Treatment Duration, Symptoms Resolution and Survival in Defibrotide-treated Patients with Veno-occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry StudyCommento a cura di: Dottor Davide Leardini e Dottor Riccardo Masetti2021-05-12T10:52:17+02:005 Febbraio 2021|
